Abstract
Intracerebral hemorrhage results in the greatest morbidity and mortality compared to other types of stroke. Although advancements have been made in the management of intracerebral hemorrhage, currently, there is no effective treatment which improves outcomes. In order to develop treatment for intracerebral hemorrhage, efforts should be focused on better understanding of the pathophysiology of disease. In addition, consideration should be given to adapting clinical trial design to address the unique clinical challenges of this disease. These challenges include the acute nature and heterogeneity of disease, smaller number of patients compared with ischemic stroke, and difficulty in recruitment and retention, to name a few. The purpose of this chapter is to explore potential solutions to some of the challenges of designing clinical trials for patients with intracerebral hemorrhage.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355–65.
Tuhrim S. Intracerebral hemorrhage – improving outcome by reducing volume? N Engl J Med. 2008;358(20):2174–6.
Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7(5):391–9.
Grotta JC, Albers G, Broderick JP, Kasner SE, Lo EH, Mendelow AD, et al. Stroke : pathophysiology, diagnosis, and management. 6th ed: Elsevier Inc; 2016. 1 online resource p.
Cheung K, Kaufmann P. Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke. 2011;42(10):2990–4.
Kenyon GM, Mendelow AD, Gregson BA, Rowan E. Obtaining regulatory approval for multicentre randomised controlled trials: experiences in the STICH II trial. Br J Neurosurg. 2011;25(3):352–6.
Jadad AR, Enkin M, Jadad AR. Randomized controlled trials: questions, answers, and musings. Blackwell Publishing; Malden, Massachusetts. 2nd ed. xxiv, 136 p.
Slyter H. Ethical challenges in stroke research. Stroke. 1998;29(8):1725–9.
Masuca SR, Das DS, Delano D, Irani M, Pandurengan R, Barreto AD, et al. Abstract 3769: barriers to obtaining informed consent in acute stroke clinical trials. Stroke. 2012;43(Suppl 1):A3769-A.
Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.
Stunkel L, Benson M, McLellan L, Sinaii N, Bedarida G, Emanuel E, et al. Comprehension and informed consent: assessing the effect of a short consent form. IRB. 2010;32(4):1–9.
Wu TC, Sarraj A, Jacobs A, Shen L, Indupuru H, Biscamp D, et al. Telemedicine-guided remote enrollment of patients into an acute stroke trial. Ann Clin Trans Neurol. 2015;2(1):38–42.
Alfredo Caceres J, Greer DM, Goldstein JN, Viswanathan A, Suarez JI, Brau L, et al. Enrollment of research subjects through telemedicine networks in a multicenter acute intracerebral hemorrhage clinical trial: design and methods. J Vasc Intervent Neurol. 2014;7(3):34–40.
Switzer JA, Hall CE, Close B, Nichols FT, Gross H, Bruno A, et al. A telestroke network enhances recruitment into acute stroke clinical trials. Stroke. 2010;41(3):566–9.
U.S. Department of Health and Human Services Food, Drug Administration Office of Good Clinical Practice Center for Drug Evaluation, Research Center for Biologics Evaluation, Research Center for Devices, Radiological Health. Guidance for institutional review boards. Clinical investigators, and sponsors; exception from informed consent requirements for emergency research. Washington, DC: U. S. Food and Drug Administration; 2013.
Bateman BT, Meyers PM, Schumacher HC, Mangla S, Pile-Spellman J. Conducting stroke research with an exception from the requirement for informed consent. Stroke. 2003;34(5):1317–23.
Halperin H, Paradis N, Mosesso V Jr, Nichol G, Sayre M, Ornato JP, et al. Recommendations for implementation of community consultation and public disclosure under the Food and Drug Administration’s “Exception from informed consent requirements for emergency research”: a special report from the American Heart Association Emergency Cardiovascular Care Committee and Council on Cardiopulmonary, Perioperative and Critical Care: endorsed by the American College of Emergency Physicians and the Society for Academic Emergency Medicine. Circulation. 2007;116(16):1855–63.
Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371(26):2457–66.
Dickert NW, Scicluna VM, Baren JM, Biros MH, Fleischman RJ, Govindarajan PR, et al. Patients’ perspectives of enrollment in research without consent: the patients’ experiences in emergency research-progesterone for the treatment of traumatic brain injury study. Crit Care Med. 2015;43(3):603–12.
Zaidat OO, Liebeskind DS, Edgell RC, Amlie-Lefond CM, Kalia JS, Alexandrov AV. Clinical trial design for endovascular ischemic stroke intervention. Neurology. 2012;79(13 Suppl 1):S221–33.
Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurol. 2015;72(5):582–8.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (London, England). 2010;375(9727):1695–703.
Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.
Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1.
Flaherty M, Jauch E. Spot sign for predicting and treating ICH growth study (STOP-IT) [updated 6/2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00810888; NLM Identifier: NCT00810888.
Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med. 2001;29(3):635–40.
Varelas PN, Schultz L, Conti M, Spanaki M, Genarrelli T, Hacein-Bey L. The impact of a neuro-intensivist on patients with stroke admitted to a neurosciences intensive care unit. Neurocrit Care. 2008;9(3):293–9.
Burns JD, Green DM, Lau H, Winter M, Koyfman F, DeFusco CM, et al. The effect of a neurocritical care service without a dedicated neuro-ICU on quality of care in intracerebral hemorrhage. Neurocrit Care. 2013;18(3):305–12.
Jaffe J, AlKhawam L, Du H, Tobin K, O’Leary J, Pollock G, et al. Outcome predictors and spectrum of treatment eligibility with prospective protocolized management of intracerebral hemorrhage. Neurosurgery. 2009;64(3):436–45; discussion 45–6.
Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973–84.
Albers GW, Bogousslavsky J, Bozik MA, Brass LM, Broderick JP, Fisher M, Goldstein LB, Salazar-Grueso E, Zivin JA, Akitsuki S, Aranko K, Ashwood T, Atkinson RP, Bell RD, Brott TG, Cady WJ, Caplan LR, Coggins S, Cramer S, Cyrus P, Dayno J, Donald Easton J, Elliott PJ, Finklestein SP, Furlan AJ, Gamzu E, Glasky MS, Gordon K, Gorelick PB, Greenwood DT, Grotta JC, Gunn K, Hachinski V, Hacke W, Hall ED, Hsu CY, Michael Humphreys D, Ishikawa H, Jacobs AJ, Kaste M, Koroshetz WJ, Krams M, Lauritano AA, Leclerc J, Lees KR, Lesko L, Levine SR, Levy DE, Li F, Lyden PD, Masayasu H, McDermott J, Meibach RC, Meya U, Miyairi K, Niidome T, Oeda J, Michael Poole R, Ron ES, Sacco RL, Saltarelli MD, Shimizu K, Shook BJ, Soehngen M, Soehngen W, Stamler DA, Styren SD, Teal PA, Tilley BC, Traystman RJ, Walker MD, Wallin BA, Warach S, Ward DP, Wessel TC, Wettstein J, Stroke Therapy Academic Industry Roundtable II (STAIR-II), Writing Committee. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32(7):1598.
Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009;72(15):1310–5.
Stafinski T, Menon D, Nardelli A, Bakal J, Ezekowitz J, Tymchak W, et al. Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. Am Heart J. 2015;169(1):122–31.e22.
Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5(7):603–12.
Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033–43.
Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener H-C, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage. Stroke. 2007;38(8):2262.
Baharoglu MI, Cordonnier C, Salman RA-S, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13.
Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet (London, England). 2005;365(9457):387–97.
Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013;382(9890):397–408.
Hanley DF, CLEAR III Investigators. Clot lysis: evaluating accelerated resolution of intraventricular hemorrhage (CLEAR III) results. International stroke conference, 2016; Los Angeles California; Oral Abstract LB12. 2016.
Sangha N, Irani M, Peng H, Rahbar MH, Martinez R, Barreto AD, Savitz SI, Wu T, Lopez G, Misra V, Ifejika N, Grotta JC, Gonzales NR. Longitudinal assessment of functional outcome in intracerebral hemorrhage. European stroke conference, Lisbon. 2012(Abstract #330).
The Specifications Manual for Joint Commission National Quality Measures (Version 2016A1) is periodically updated by The Joint Commission.
Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–60.
Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63.
Gonzales NR. Ongoing clinical trials in intracerebral hemorrhage. Stroke. 2013;44(6 suppl 1):S70.
Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK. Communicating with participants during the conduct of multi-center clinical trials. Clinl Trials (London, England). 2016;13:592.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010. www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf on 11/20/16.
Rahbar MH, Dickerson AS, Cai C, Pedroza C, Hessabi M, Shen L, et al. Methodological issues for designing and conducting a multicenter, international clinical trial in acute stroke: experience from ARTSS-2 trial. Contemp Clin Trials. 2015;44:139.
Connor JT, Broglio KR, Durkalski V, Meurer WJ, Johnston KC. The stroke hyperglycemia insulin network effort (SHINE) trial: an adaptive trial design case study. Trials. 2015;16:72.
Elkind MS, Sacco RL, Macarthur RB, Peerschke E, Neils G, Andrews H, et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis (Basel, Switzerland). 2009;28(3):266–75.
Gonzales NR, Shah J, Sangha N, Sosa L, Martinez R, Shen L, et al. Design of a prospective, dose-escalation study evaluating the safety of pioglitazone for hematoma resolution in intracerebral hemorrhage (SHRINC). Int J Stroke Off J Int Stroke Soc. 2013;8(5):388–96.
Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010;41(10):2283–7.
Grieve AP, Krams M. ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clin Trials, (London, England). 2005;2(4):340–51; discussion 52–8, 64–78.
Howard G. Nonconventional clinical trial designs: approaches to provide more precise estimates of treatment effects with a smaller sample size, but at a cost. Stroke. 2007;38(2 Suppl):804–8.
Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:209–34.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Olowu, A., Gonzales, N.R. (2018). Clinical Trial Design in Subjects with Intracerebral Hemorrhage. In: Ovbiagele, B., Qureshi, A. (eds) Intracerebral Hemorrhage Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-77063-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-77063-5_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-77062-8
Online ISBN: 978-3-319-77063-5
eBook Packages: MedicineMedicine (R0)